Analysis of patent trends and innovations in major varieties of Chinese medicinal materialsZHANG Jing-yue, WEI Xi, HE Wen-jing, LI Wen1009-1016
A new drug for schizophrenia:CobenfyZHANG Hong-qiang, HUO Xiao-ning, FENG Jun, LIU Xin-fa, ZHANG Li, WU Qi1017-1021
Real-world evidence to support the FDA's regulatory review for new drug approvalsLI Ze-yu, YANG Yue1022-1031
Research and consideration on electronic submission system for drug registration in foreign countriesYIN Cui-xiang, LI Hai-ling, ZHANG Yuan1032-1034
Analysis and research on common problems in the registration and inspection of chemical drugs produced overseasLI Wen-long, WANG Xue-lei, TAN Li-yuan, WEI Jing-jing, MEN Ying-xuan, WU Zhao-yang, SHI Jia, WANG Yan, ZHANG Qing-sheng1035-1039
Determination of non-inferiority margins in clinical trials of antipsychotic drugsCHENG Qing-qing, WANG Rui, WANG Jing-jing, TANG Dai-mao, ZHANG Ling-xiao, XU Ling, YI Fang, YANG Juan, LÜ Ying-hua, ZHENG Qing-shan, SHEN Yi-feng, LI Hua-fang, SI Tian-mei1040-1045
Analysis of the registration characteristics of pancreatic cancer clinical trials based on data from ClinicalTrials.govHE Jing-long, XIE Lei, XU Yang-mei, CHENG Bin1046-1052
A single-dose and 4-week repeat-dose toxicity and toxicokinetic study of pediatric Reduning injection in weaning Beagle dogsSUN Zu-yue, LI Fang, ZHENG Chi-yang, CHEN Ding-shi, CHEN Li-fen, XU Li, YAN Han, WANG Zhong-hui, LI Lei, WANG Fen, ZHOU Li1053-1062
Progress in the application of in vitro models for teratogenicity research in drug developmentFANG Ya-li, LI Shen-ning, ZHOU Chang-hui, CUI Wen-teng, FENG Tian-yi, CHANG Yan1063-1069
Progress in covalent site-specific labeling strategy and its application in radiopharmaceuticalsWU Qiu-yan, CHU Jin-yu, LIANG Xu-rui, SU Peng-yuan, ZHANG Ya, DENG Wan-su, HUANG He, ZHANG Tao1070-1076